Home>Topics>Stocks>Lexicon Pharmaceuticals

Lexicon Pharmaceuticals LXRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. For Lexicon Pharmaceuticals , No News Remains Bad News

      Headlines

      Mon, 11 Aug 2014

      By Stephen Simpson, CFA : The frustrating wait for the key driver at Lexicon Pharmaceuticals (NASDAQ: LXRX ) - a clinical development and marketing partner for LX4211 - goes on. While management spent a lot of time on its earnings call

    2. Lexicon Pharmaceuticals' ( LXRX ) CEO Lonnel Coats on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Sun, 10 Aug 2014

      Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX ) Q2 2014 Results Earnings Conference Call August 7 ..... this time, I would like to welcome everyone to the Lexicon Pharmaceuticals ’ Second Quarter Earnings Conference Call. All lines

    3. New Morningstar Analyst Report for Lexicon Pharmaceuticals Inc

      Stock Reports

      Fri, 8 Aug 2014

      background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising

    4. More on Lexicon Pharma Q2 results

      Headlines

      Thu, 7 Aug 2014

      Lexicon Pharmaceuticals ( LXRX -3.6% ) Q2 results : Revenues: $676K (+215.9%); Operating Expenses: $26.8M (-7.1%); Operating Loss

    5. Lexicon Pharmaceuticals EPS in-line, beats on revenue

      Headlines

      Thu, 7 Aug 2014

      Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q2 EPS of -$0.05 in-line. Revenue of $0.7M (+233.3% Y/Y) beats by $0.58M . Press Release Post your comment!

    6. Premarket Gainers / Losers

      Headlines

      Wed, 9 Jul 2014

      Gainers: ACST +16% . LXRX +13% . NQ +9% . USU +9% . AAL +6% . TXMD +5% . CAMT +5% . Losers: GIMO -33% . TCS -15% . PT -7% . Post your comment!

    7. Morning Star Ratings

      Commentary

      Wed, 7 May 2014

      I guess I should address this to Morning Star but don't find a way. My question is how can you cover in analysis a stock such as LXRX with 149 employes and not cover in your analysis a stock such as HLS, makes me wonder about how you pick your stocks to analyse. Jack

    8. lxrx not for now.

      Commentary

      Fri, 4 Apr 2014

      Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,

    9. M* 5 Star Stocks

      Commentary

      Sat, 22 Mar 2014

      the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX

    10. LXRX . Morningstar rating change

      Commentary

      Fri, 7 Feb 2014

      Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?

    « Prev1234Next »
    Content Partners